TECH CULTURES: Politecnico di Torino opens a call for expression of interest for guest curators in the Biennale Tecnologia 2026 festival 6-12-2024, 22:46

Io Therapeutics, Inc., presented data from studies of IRX4204, the company’s phase II clinical development stage, highly selective third generation RXR nuclear receptor agonist compound, supporting its potential use for prevention and treatment of normal 10-07-2024, 07:00

Digital Realty enters Malaysia, strengthening Southeast Asia’s digital backbone 20-01-2026, 00:00